Drug intelligence / Profile preview

lerdelimumab

Development stage: Discontinued
Lead developer: AstraZeneca
Modality: Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Ophthalmic

Overview

Lerdelimumab is a human monoclonal antibody developed as an immunosuppressive agent targeting transforming growth factor beta 2 (TGF beta 2). Its primary mechanism of action is the inhibition of TGF beta 2, a cytokine involved in fibrotic processes. Lerdelimumab was investigated for reducing scarring after glaucoma drainage surgery and showed potential activity in other ocular diseases such as cataract, retinopathy, and connective tissue diseases. The drug was granted European orphan drug status for preventing scar formation post-glaucoma surgery but development was discontinued after unsuccessful clinical trial results[1][3][6][8].

Brand names: Trabio
Other names: lerdelimumab

Targets

TGFB2 (Transforming growth factor beta 2)

Beyond the preview

Go deeper on lerdelimumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lerdelimumab.

Explore the full profile